Pacer Advisors
CHRS icon

Pacer Advisors’s Coherus Oncology CHRS Stock Holding History

Pacer Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-105,431
Closed -$1.54M – 1437
2021
Q1 		$1.54M Buy
105,431
+78,830
+296% +$1.34M 0.03% 598
2020
Q4 		$462K Buy
26,601
+5,472
+26% +$97.4K 0.01% 1002
2020
Q3 		$388K Buy
21,129
+11,339
+116% +$211K 0.01% 1066
2020
Q2 		$175K Buy
+9,790
New +$166K ﹤0.01% 815
2018
Q4 		– Sell
-4,767
Closed -$79K – 628
2018
Q3 		$79K Buy
+4,767
New +$84.5K ﹤0.01% 1113
2018
Q1 		– Sell
-1,725
Closed -$15K – 1053
2017
Q4 		$15K Buy
+1,725
New +$18.5K ﹤0.01% 1117

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Pacer Advisors's CHRS Position: Q2 2021 in Review

Pacer Advisors sold out of Coherus Oncology (CHRS) in Q2 2021, closing a stake of 105,431 shares — an estimated $1.54M sold.

Pacer Advisors first reported a position in CHRS in Q4 2017 and held it in 6 quarters. The position peaked at $1.54M in Q1 2021. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2021.

  • Pacer Advisors reported no remaining Coherus Oncology position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 105,431 Coherus Oncology shares in Q2 2021, an estimated $1.54M.
  • Pacer Advisors first reported a position in Coherus Oncology in Q4 2017 and held it in 6 quarters.
  • Pacer Advisors's Coherus Oncology position peaked at $1.54M in Q1 2021.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.